Volume : 13, Issue : 08, August – 2026

Title:

FORMULATION AND EVALUATION OF SUSTAINED RELEASE TABLETS OF PENTOXIFYLLINE

Authors :

Tejal Nandan Pawar, Dr. S. S. Angadi, Reshma Patil, Dr. Vandana Patil

Abstract :

The present study aimed to develop and evaluate sustained-release matrix tablets of Pentoxifylline using Hydroxypropyl Methylcellulose K4M (HPMC K4M) as a release-retarding polymer. Pentoxifylline has a short biological half-life and requires frequent administration, making it a suitable candidate for sustained-release delivery. Preformulation studies including organoleptic evaluation, solubility, melting point, UV spectrophotometric analysis and FTIR compatibility were performed. Seven formulations (F1–F7) were prepared by wet granulation using different concentrations of HPMC K4M. The prepared granules showed satisfactory flow and compressibility properties, while tablets exhibited acceptable weight variation, thickness, hardness, friability and drug-content uniformity. In-vitro dissolution studies demonstrated a concentration-dependent retardation of drug release with increasing HPMC K4M concentration. Formulation F5 was selected as the optimized formulation based on its satisfactory pharmaceutical characteristics and sustained-release profile. Kinetic analysis showed that drug release followed the Higuchi model predominantly, with diffusion, polymer relaxation and erosion contributing to the release mechanism.
Keywords: Pentoxifylline, Sustained-release matrix tablet, HPMC K4M, Wet granulation, Drug release, Higuchi model, Diffusion, Matrix system.

Cite This Article:

Please cite this article in press Tejal N Pawar et al., Formulation And Evaluation Of Sustained Release Tablets Of Pentoxifylline. Indo Am. J. P. Sci, 2026; 13(08).

REFERENCES:

1. Vyas SP, Khar RK. Controlled drug delivery: Concepts and advances. Vallabh Prakashan; 2002.
2. Aulton ME. Aulton’s pharmaceutics: The design and manufacture of medicines. 5th ed. Elsevier; 2018.
3. Ratnaparkhi MP, Gupta JP. Sustained release oral drug delivery system—An overview. Int J Pharma Res Rev. 2013;2(3):11–21.
4. Qiu Y, Zhang GGZ, Wise DL, Porter SC. Modified-release oral drug delivery systems. In: Developing Solid Oral Dosage Forms. Academic Press; 2009. p.519–554.
5. Nokhodchi A, Raja S, Patel P, Asare-Addo K. The role of oral controlled release matrix tablets in drug delivery systems. BioImpacts. 2012;2(4):175–187.
6. Rathore AS, Jat RC, Sharma N, Tiwari R. Matrix tablet as controlled drug delivery system: An overview. Int J Res Dev Pharm Life Sci. 2013;2(4):482–492.
7. Colombo P. Swelling-controlled release in hydrogel matrices for oral route. Adv Drug Deliv Rev. 1993;11(1–2):37–57.
8. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose. Adv Drug Deliv Rev. 2001;48(2–3):139–157.
9. Rekhi GS, Jambhekar SS, Ford JL. Effect of formulation factors on drug release from hydrophilic matrix tablets. J Pharm Pharmacol. 1999;51(8):1005–1013.
10. Nokhodchi A. An overview of the effect of formulation and processing variables on the release of drugs from hydrophilic matrices. J Pharm Pharm Sci. 2005;8(1):18–25.
11. Khamanga SMM, Walker RB. Matrix tablets as drug delivery systems. Pharm Dev Technol. 2011;16(3):227–238.
12. Colombo P, Bettini R, Santi P, De Ascentiis A, Peppas NA. Analysis of the swelling and release mechanisms from drug delivery systems with emphasis on drug solubility and water transport. J Control Release. 1996;39(2–3):231–237.
13. Ford JL. Design and evaluation of hydroxypropyl methylcellulose matrix tablets for oral controlled release. Drug Dev Ind Pharm. 1999;25(9):1085–1095.
14. Siepmann J, Kranz H, Bodmeier R, Peppas NA. HPMC-matrices for controlled drug delivery: A new model combining diffusion, swelling, and dissolution mechanisms. Pharm Res. 1999;16(11):1748–1756.
15. Higuchi T. Mechanism of sustained-action medication: Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52(12):1145–1149.
16. Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123–133.
17. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217–223.
18. Colombo P, Bettini R, Massimo G, Catellani PL, Vitali T, Peppas NA. Drug diffusion front movement is important in drug release control from swellable matrix tablets. J Pharm Sci. 1995;84(8):991–997.
19. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15(1):25–35.
20. Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation. Ind Eng Chem. 1931;23(8):923–931.
21. Peppas NA, Sahlin JJ. A simple equation for the description of solute release. III. Coupling of diffusion and relaxation. Int J Pharm. 1989;57(2):169–172.
22. Siepmann J, Peppas NA. Higuchi equation: Derivation, applications, use and misuse. Int J Pharm. 2011;418(1):6–12.
23. Carr RL. Evaluating flow properties of solids. Chem Eng. 1965;72(3):163–168.
24. United States Pharmacopeial Convention. United States Pharmacopeia 46–National Formulary 41. USP Convention; 2023.
25. International Council for Harmonisation. ICH guideline Q1A(R2): Stability testing of new drug substances and products. ICH Harmonised Guideline; 2023.

Volume : 13, Issue : 08, August – 2026

Title:

EVALUATION OF ANTIHYPERLIPIDEMIC ACTIVITY OF SAPINDUS EMARGINATUS IN RATS

Authors :

Chinthala Jamima*, Dr.R.narasimha Rao, Dr.N. Raghunandhan

Abstract :

Obesity and hyperlipidemia have become major disorders predominantly causing prevailing cardiovascular diseases and ultimately death. The prolonged use of anti-obesity drugs and statins for reducing obesity and blood lipid levels is leading toward adverse effects of kidneys and muscles, specifically rhabdomyolysis. The objective of this study is to evaluate potential of seeds of Sapindus emarginatus against hyperlipidemia. In this model of Hyperlipidemia, 30 adult male wistar rats (200-250gms) were evenly divided into 5 groups in both groups. Group-1 and Group-2 served as untreated and model controls respectively, while Group-3, 4 and 5 were the treatments groups which were simultaneously treated with standard, 100 and 200 mg/kg extract respectively along with High Fat Diet. On last day, blood samples for biochemical parameters, were obtained under inhaled diether anaesthesia. The outcomes of this study were expressed as mean standard error and data were evaluated by using analysis of variance followed by multiple comparisons. Oral administration of 100 mg/ kg and 200mg/kg body weight of Methanolic extract residual fraction of Moringa oleifera. Leaves exhibited a significant reduction (P < 0.01) in serum lipid parameters such as triglycerides, total cholesterol, low density lipoprotein (LDL), very LDL and increase in high density lipoprotein in hyperlipidemic rats when compared with hyperlipidemic control in both models. Our results demonstrated that Methanolic extract fraction of Sesbania grandiflora. Possessed significant antihyperlipidemic activity.
Keywords: Sesbania grandiflora, Cholesterol, LDL, triglycerides and antihyperlipidemic activity.

Cite This Article:

Please cite this article in press Chinthala Jamimaet al., Evaluation of Antihyperlipidemic activity of Sapindus Emarginatus in rats,, Indo Am. J. P. Sci, 2026; 13(08).

REFERENCES:

1. Amit G, Vandana S, Sidharth M. HYPERLIPIDEMIA: An Updated Review. Inter J of Biopharma & Toxicol Res 2011;1:81-89.
2. Virchow RP, Thrombose IG. In Gesammelte Abhandlungen zur Wissenschaftlichen Medicin. Frankfurt-am-Main, Meidinger Sohn & Company 1856, S 458-564.
3. Ankur rohilla, Nidhi Dagar, Seema Rohilla, Amarjeet Dahiya, Ashok Kushnoor. HYPERLIPIDEMIA- a deadly pathological condition. Inter J Curr Pharma Res 2012;4:15-18
4. Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976;295:369-77.
5. Grundy SM, Vega GL. Hypertriglyceridemia: causes and relation to coronary heart disease – Semin. Thromb. Hemost 1988;14:249-64.
6. Dargel R. Lipoproteins and the etiopathogenesis of atherosclerosis. Zentralbl Allg Pathol 1989; 135: 501-504.